NASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis $12.78 -0.19 (-1.46%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Candel Therapeutics Stock (NASDAQ:CADL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Candel Therapeutics alerts:Sign Up Key Stats Today's Range$12.76▼$13.0550-Day Range$9.40▼$13.7552-Week Range$4.35▼$14.00Volume535,343 shsAverage Volume1.25 million shsMarket Capitalization$977.93 millionP/E RatioN/ADividend YieldN/APrice Target$19.29Consensus RatingModerate Buy Company Overview Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs. In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications. The company’s research and development activities are supported by a combination of in-house expertise in viral immunology and collaborations with academic institutions and contract research organizations. Preclinical studies have demonstrated the potential of Candel’s viral platforms to reshape the tumor microenvironment and synergize with checkpoint inhibitors and other immunotherapies. Headquartered in Pittsburgh, Pennsylvania, Candel Therapeutics conducts clinical trials across multiple sites in North America and Europe. The company was founded by scientists with deep expertise in oncolytic virotherapy and has assembled a management team experienced in advancing viral therapies through regulatory interactions. As a public company listed on Nasdaq under the ticker CADL, Candel continues to expand its scientific capabilities and clinical footprint to bring innovative viral immunotherapies to patients worldwide.AI Generated. May Contain Errors. Read More Candel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCADL MarketRank™: Candel Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 319th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCandel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCandel Therapeutics has a consensus price target of $19.29, representing about 50.9% upside from its current price of $12.78.Amount of Analyst CoverageCandel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Candel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Candel Therapeutics are expected to grow in the coming year, from ($1.29) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 7.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Candel Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.01% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 10.56, which indicates bearish sentiment.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.96 News SentimentCandel Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Candel Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $390,017.00 in company stock.Percentage Held by Insiders14.30% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.93% of the stock of Candel Therapeutics is held by institutions.Read more about Candel Therapeutics' insider trading history. Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CADL Stock News HeadlinesCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comShow Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing NearsAugust 28, 2026 | rttnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 5 at 1:00 AM | Porter & Company (Ad)Candel Therapeutics to Present at September Investor ConferencesAugust 26, 2026 | globenewswire.comCandel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?August 21, 2026 | finance.yahoo.comCandel Therapeutics, Inc. (CADL)August 20, 2026 | finance.yahoo.comCandel Therapeutics (CADL) Receives a Hold from Bank of America SecuritiesAugust 15, 2026 | theglobeandmail.comCADL rises as biotech eyes first commercial product in 2027 — CEO points to ‘meaningful execution’ toward BLA submission in Q4August 13, 2026 | msn.comSee More Headlines CADL Stock Analysis - Frequently Asked Questions How have CADL shares performed this year? Candel Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, CADL shares have increased by 126.2% and is now trading at $12.78. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.28. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are Candel Therapeutics' major shareholders? Top institutional investors of Candel Therapeutics include BlackRock Inc. (6.78%), Bank of America Corp DE (0.36%), Wellington Management Group LLP (0.27%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Paul B Manning, Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, Seshu Tyagarajan, William Garrett Nichols and Charles Schoch. View institutional ownership trends. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Candel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V). Company Calendar Last Earnings8/13/2026Today9/05/2026Citigroup’s Biopharma Back to School Summit 20269/09/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/10/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CADL's financial health is in the Green zone, according to TradeSmith. CADL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CADL CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees60Year Founded1999Price Target and Rating Average Price Target for Candel Therapeutics$19.29 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+50.9%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.98% Return on Assets-48.50% Debt Debt-to-Equity Ratio0.38 Current Ratio16.09 Quick Ratio16.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book7.75Miscellaneous Outstanding Shares76,520,000Free Float65,577,000Market Cap$977.93 million OptionableOptionable Beta-0.48 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CADL) was last updated on 9/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
